VictorDjuroMD

Clinical Trials

• Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery Start of enrollment: 2019 Dec 16

  Active, not recruiting

  Phase 2, Phase 3

• A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma Start of enrollment: 2018 Dec 13

  Active, not recruiting

  Phase 2

• Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Start of enrollment: 2015 Dec 18

  Recruiting

  Phase 2

• A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer Start of enrollment: 2018 Jun 21

  Active, not recruiting

  Phase 3

• A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer Start of enrollment: 2019 May 08

  Active, not recruiting

• Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations Start of enrollment: 2019 Dec 27

  Terminated

  Phase 3

• Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01

  Active, not recruiting

  Phase 3

• A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011) Start of enrollment: 2021 Feb 25

  Active, not recruiting

  Phase 3

• Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors Start of enrollment: 2019 May 13

  Recruiting

  Phase 2

• Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study Start of enrollment: 2019 Jun 07

  Active, not recruiting

  Phase 3

• A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency Start of enrollment: 2017 Jun 13

  Active, not recruiting

  Phase 3

• Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer Start of enrollment: 2014 Jan 22

  Active, not recruiting

  Phase 3

• S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08

  Active, not recruiting

  Phase 3

• A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer Start of enrollment: 2020 Feb 06

  Active, not recruiting

  Phase 3

• Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer Start of enrollment: 2018 Sep 27

  Active, not recruiting

  Phase 3

• Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Start of enrollment: 2016 Jun 30

  Completed

  Phase 3

• 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer Start of enrollment: 2009 Jun 01

  Active, not recruiting

  Phase 2

• Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer Start of enrollment: 2006 Jul 01

  Completed

  Phase 1, Phase 2

• A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer Start of enrollment: 2022 Feb 12

  Active, not recruiting

  Phase 2, Phase 3

• A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer Start of enrollment: 2020 Dec 21

  Recruiting

  Phase 3

• Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer Start of enrollment: 2022 Mar 14

  Recruiting

  Phase 3

• Study of Magrolimab Given Together With FOLFIRI/BEV in Patients With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) Start of enrollment: 2022 Jul 08

  Active, not recruiting

  Phase 2

• 177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2022 Feb 14

  Active, not recruiting

  Phase 3

• A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2023 Mar 29

  Recruiting

  Phase 3

• A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) Start of enrollment: 2023 Mar 23

  Recruiting

  Phase 3

• Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Start of enrollment: 2022 Sep 07

  Recruiting

  Phase 3

• Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease Start of enrollment: 2022 Mar 10

  Recruiting

  Phase 2, Phase 3

• CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer Start of enrollment: 2021 Dec 15

  Recruiting

• A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) Start of enrollment: 2023 Feb 08

  Recruiting

  Phase 3

• Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma Start of enrollment: 2024 Feb 05

  Recruiting

  Phase 3

• Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) Start of enrollment: 2017 Jun 29

  Active, not recruiting

  Phase 3

• A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2023 Sep 28

  Recruiting

  Phase 2

• A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Patients With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis Start of enrollment: 2024 May 31

  Recruiting

  Phase 2

• Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008) Start of enrollment: 2021 Jun 25

  Recruiting

  Phase 2

• Join now to see all